Mouse Transplant Models for Evaluating the Oncogenic Risk of a Self-Inactivating XSCID Lentiviral Vector

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Zhou, Sheng ^a   Ma, Zhijun ^a   Lu, Taihe ^a   Janke, Laura ^a   Gray, John T ^a   Sorrentino, Brian P ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INITIATION FACTOR 1A; LENTIVIRUS VECTOR; PROTEIN SERINE THREONINE KINASE; RETROVIRUS VECTOR; ELONGATION FACTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; CANCER RISK; CELL TRANSFORMATION; CONTROLLED STUDY; EXPERIMENTAL MODEL; FEMALE; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MOUSE; NONHUMAN; SAFETY; T CELL LEUKEMIA; VIRUS INACTIVATION; X LINKED SEVERE COMBINED IMMUNODEFICIENCY; ANIMAL; BONE MARROW CELL; GENE ORDER; GENE VECTOR; GENETICS; HUMAN; KNOCKOUT MOUSE; LENTIVIRINAE; METABOLISM; PATHOLOGY; SPLEEN FOCUS FORMING VIRUS; T LYMPHOCYTE; VIROLOGY; VIRUS CELL TRANSFORMATION;

MUS; SPLEEN FOCUS-FORMING VIRUS;

ANIMALS; BONE MARROW CELLS; CELL TRANSFORMATION, NEOPLASTIC; CELL TRANSFORMATION, VIRAL; FEMALE; GENE ORDER; GENETIC VECTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LENTIVIRUS; LYMPHOMA, B-CELL; MICE; MICE, KNOCKOUT; MYELOID CELLS; PEPTIDE ELONGATION FACTOR 1; SPLEEN FOCUS-FORMING VIRUSES; T-LYMPHOCYTES; X-LINKED COMBINED IMMUNODEFICIENCY DISEASES;

EID: 84876579026     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062333     Document Type: Article

References (50)

1. Hacein-Bey-Abina S, Hauer J, Lim A, Picard C, Wang GP, et al. (2010) Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 363: 355-364.
2. Gaspar HB, Cooray S, Gilmour KC, Parsley KL, Adams S, et al. (2011) Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med 3: 97ra79.
3. Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, et al. (2009) Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 360: 447-458.
4. Candotti F, Shaw KL, Muul L, Carbonaro D, Sokolic R, et al. (2012) Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood 120: 3635-3646.
5. Gaspar HB, Cooray S, Gilmour KC, Parsley KL, Zhang F, et al. (2011) Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med 3: 97ra80.
6. Shaw KL, Kohn DB, (2011) A tale of two SCIDs. Sci Transl Med 3: 97ps36.
7. Boztug K, Schmidt M, Schwarzer A, Banerjee PP, Diez IA, et al. (2010) Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med 363: 1918-1927.
8. Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, et al. (2010) Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 467: 318-322.
9. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, et al. (2009) Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326: 818-823.
10. Deichmann A, Hacein-Bey-Abina S, Schmidt M, Garrigue A, Brugman MH, et al. (2007) Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J Clin Invest 117: 2225-2232.
11. Hacein-Bey-Abina S, von KC, Schmidt M, McCormack MP, Wulffraat N, et al. (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419.
12. Baum C, (2011) Parachuting in the epigenome: the biology of gene vector insertion profiles in the context of clinical trials. EMBO Mol Med 3: 75-77.
13. Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, et al. (2008) Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 118: 3143-3150.
14. McCormack MP, Rabbitts TH, (2004) Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 350: 913-922.
15. Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, et al. (2008) Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118: 3132-3142.
16. Rivat C, Santilli G, Gaspar HB, Thrasher AJ, (2012) Gene therapy for primary immunodeficiencies. Hum Gene Ther 23: 668-675.
17. Zhou S, Mody D, DeRavin SS, Hauer J, Lu T, et al. (2010) A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells. Blood 116: 900-908.
18. Nienhuis AW, Dunbar CE, Sorrentino BP, (2006) Genotoxicity of retroviral integration in hematopoietic cells. Mol Ther 13: 1031-1049.
19. Will E, Bailey J, Schuesler T, Modlich U, Balcik B, et al. (2007) Importance of murine study design for testing toxicity of retroviral vectors in support of phase I trials. Mol Ther 15: 782-791.
20. Corrigan-Curay J, Cohen-Haguenauer O, O'Reilly M, Ross SR, Fan H, et al. (2012) Challenges in vector and trial design using retroviral vectors for long-term gene correction in hematopoietic stem cell gene therapy. Mol Ther 20: 1084-1094.
21. Lo M, Bloom ML, Imada K, Berg M, Bollenbacher JM, et al. (1999) Restoration of lymphoid populations in a murine model of X-linked severe combined immunodeficiency by a gene-therapy approach. Blood 94: 3027-3036.
22. Bunting KD, Sangster MY, Ihle JN, Sorrentino BP, (1998) Restoration of lymphocyte function in Janus kinase 3-deficient mice by retroviral-mediated gene transfer. Nat Med 4: 58-64.
23. Otsu M, Anderson SM, Bodine DM, Puck JM, O'Shea JJ, et al. (2000) Lymphoid development and function in X-linked severe combined immunodeficiency mice after stem cell gene therapy. Mol Ther 1: 145-153.
24. Soudais C, Shiho T, Sharara LI, Guy-Grand D, Taniguchi T, et al. (2000) Stable and functional lymphoid reconstitution of common cytokine receptor gamma chain deficient mice by retroviral-mediated gene transfer. Blood 95: 3071-3077.
25. Ryu BY, Evans-Galea MV, Gray JT, Bodine DM, Persons DA, et al. (2008) An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activation. Blood 111: 1866-1875.
26. Modlich U, Bohne J, Schmidt M, von KC, Knoss S, et al. (2006) Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 108: 2545-2553.
27. Kustikova O, Fehse B, Modlich U, Yang M, Dullmann J, et al. (2005) Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 308: 1171-1174.
28. Calmels B, Ferguson C, Laukkanen MO, Adler R, Faulhaber M, et al. (2005) Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells. Blood 106: 2530-2533.
29. Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, et al. (2006) Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12: 401-409.
30. Modlich U, Schambach A, Brugman MH, Wicke DC, Knoess S, et al. (2008) Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16. Leukemia 22: 1519-1528.
31. Montini E, Cesana D, Schmidt M, Sanvito F, Bartholomae CC, et al. (2009) The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 119: 964-975.
32. Shou Y, Ma Z, Lu T, Sorrentino BP, (2006) Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. Proc Natl Acad Sci USA 103: 11730-11735.
33. Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, et al. (2006) Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 24: 687-696.
34. Lachmann S, Jevons A, De RM, Casamassima A, Radtke S, et al. (2011) Regulatory domain selectivity in the cell-type specific PKN-dependence of cell migration. PLoS One 6: e21732.
35. Scobie L, Hector RD, Grant L, Bell M, Nielsen AA, et al. (2009) A novel model of SCID-X1 reconstitution reveals predisposition to retrovirus-induced lymphoma but no evidence of gammaC gene oncogenicity. Mol Ther 17: 1031-1038.
36. Ginn SL, Liao SH, Dane AP, Hu M, Hyman J, et al. (2010) Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype correction independent of insertional mutagenesis and gammac overexpression. Mol Ther 18: 965-976.
37. Sharara LI, Andersson A, Guy-Grand D, Fischer A, DiSanto JP, (1997) Deregulated TCR alpha beta T cell population provokes extramedullary hematopoiesis in mice deficient in the common gamma chain. Eur J Immunol 27: 990-998.
38. Treanor LM, Volanakis EJ, Zhou S, Lu T, Sherr CJ, et al. (2011) Functional interactions between Lmo2, the Arf tumor suppressor, and Notch1 in murine T-cell malignancies. Blood 117: 5453-5462.
39. Haines DC, Chattopadhyay S, Ward JM, (2001) Pathology of aging B6;129 mice. Toxicol Pathol 29: 653-661.
40. Ward JM, (2006) Lymphomas and leukemias in mice. Exp Toxicol Pathol 57: 377-381.
41. Boniver J, Humblet C, Rongy AM, Delvenne C, Delvenne P, et al. (1990) Cellular aspects of the pathogenesis of radiation-induced thymic lymphomas in C57 BL mice (review). In Vivo 4: 41-43.
42. Rangarajan A, Hong SJ, Gifford A, Weinberg RA, (2004) Species- and cell type-specific requirements for cellular transformation. Cancer Cell 6: 171-183.
43. Osawa M, Hanada K, Hamada H, Nakauchi H, (1996) Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. Science 273: 242-245.
44. Zhang CC, Lodish HF, (2008) Cytokines regulating hematopoietic stem cell function. Curr Opin Hematol 15: 307-311.
45. Throm RE, Ouma AA, Zhou S, Chandrasekaran A, Lockey T, et al. (2009) Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection. Blood 113: 5104-5110.
46. Paige CJ, Kincade PW, Ralph P, (1978) Murine B cell leukemia line with inducible surface immunoglobulin expression. J Immunol 121: 641-647.
47. Arnold LW, LoCascio NJ, Lutz PM, Pennell CA, Klapper D, et al. (1983) Antigen-induced lymphomagenesis: identification of a murine B cell lymphoma with known antigen specificity. J Immunol 131: 2064-2068.
48. Benjelloun F, Garrigue A, Demerens-de CC, Soulas-Sprauel P, Malassis-Seris M, et al. (2008) Stable and functional lymphoid reconstitution in artemis-deficient mice following lentiviral artemis gene transfer into hematopoietic stem cells. Mol Ther 16: 1490-1499.
49. Parsley TB, Chen B, Geletka LM, Nuss DL, (2002) Differential modulation of cellular signaling pathways by mild and severe hypovirus strains. Eukaryot Cell 1: 401-413.
50. Towers GJ, Stockholm D, Labrousse-Najburg V, Carlier F, Danos O, et al. (1999) One step screening of retroviral producer clones by real time quantitative PCR. J Gene Med 1: 352-359.